Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb rounds out lens family

This article was originally published in The Gray Sheet

Executive Summary

With the launch of its PureVision multi-focal contact lens for vision correction in people with presbyopia, announced Feb. 23, Bausch & Lomb offers a full range of silicone hydrogel lenses, which also includes PureVision spherical and PureVision toric designs, according to the company. The multi-focal lens, which is uniquely indicated for daily wear or for extended wear up to 30 days, is the first of its type to reach the U.S. market, the firm says. Though the multi-focal lens was approved by FDA last spring, roll-out has been delayed while the company worked to increase its manufacturing capacity (1"The Gray Sheet" Dec. 5, 2005, p. 8)...

You may also be interested in...



Bausch & Lomb To Compete In Silicone Hydrogel Lens Market With PureVision

Bausch & Lomb predicts that a recent increase in manufacturing capacity will allow its PureVision SVS line of silicone hydrogel contact lenses to take market share from Ciba Vision and Johnson & Johnson/Vistakon

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel